Lipid Nanoparticles for mRNA Delivery to Enhance Cancer Immunotherapy

Messenger RNA (mRNA) is being developed by researchers as a novel drug for the treatment or prevention of many diseases. However, to enable mRNA to fully exploit its effects in vivo, researchers need to develop safer and more effective mRNA delivery systems that improve mRNA stability and enhance th...

Full description

Saved in:
Bibliographic Details
Published in:Molecules (Basel, Switzerland) Switzerland), 2022-08, Vol.27 (17), p.5607
Main Authors: Wang, Hong-Li, Wang, Zhi-Gang, Liu, Shu-Lin
Format: Article
Language:English
Subjects:
Antigens
Biomedical materials
Cancer
Cancer immunotherapy
Cancer therapies
Cell growth
Chemotherapy
Clinical trials
Cytokines
Drug delivery
Drug therapy
FDA approval
Health services
Human papillomavirus
Immune system
Immunotherapy
Leukemia
lipid nanoparticles
Lipids
Lymphocytes
Medical research
Messenger RNA
mRNA delivery
mRNA stability
mRNA vaccines
Nanoparticles
Prevention
Radiation therapy
Review
System effectiveness
Tumor necrosis factor-TNF
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c537t-c02e98ad93a3dfa7a3ec1455cd602c51eda7ae03e26468ebbb90e01e0e03c56a3
cites cdi_FETCH-LOGICAL-c537t-c02e98ad93a3dfa7a3ec1455cd602c51eda7ae03e26468ebbb90e01e0e03c56a3
container_end_page
container_issue 17
container_start_page 5607
container_title Molecules (Basel, Switzerland)
container_volume 27
creator Wang, Hong-Li
Wang, Zhi-Gang
Liu, Shu-Lin
description Messenger RNA (mRNA) is being developed by researchers as a novel drug for the treatment or prevention of many diseases. However, to enable mRNA to fully exploit its effects in vivo, researchers need to develop safer and more effective mRNA delivery systems that improve mRNA stability and enhance the ability of cells to take up and release mRNA. To date, lipid nanoparticles are promising nanodrug carriers for tumor therapy, which can significantly improve the immunotherapeutic effects of conventional drugs by modulating mRNA delivery, and have attracted widespread interest in the biomedical field. This review focuses on the delivery of mRNA by lipid nanoparticles for cancer treatment. We summarize some common tumor immunotherapy and mRNA delivery strategies, describe the clinical advantages of lipid nanoparticles for mRNA delivery, and provide an outlook on the current challenges and future developments of this technology.
doi_str_mv 10.3390/molecules27175607
format article
fullrecord <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_be256023492d4d59a136e330870cecc8</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A745962145</galeid><doaj_id>oai_doaj_org_article_be256023492d4d59a136e330870cecc8</doaj_id><sourcerecordid>A745962145</sourcerecordid><originalsourceid>FETCH-LOGICAL-c537t-c02e98ad93a3dfa7a3ec1455cd602c51eda7ae03e26468ebbb90e01e0e03c56a3</originalsourceid><addsrcrecordid>eNptklurEzEQxxdRPBf9AL4t-OJLj5NMspcXofRUT6EcQfQ5ZJPZNmU3qdndA_32prbIqUpgMkz-8wtzybJ3DO4Qa_jYh47M1NHAS1bKAsoX2TUTHGYIon75zL_KboZhB8CZYPJ1doUFVIAlXmfLtds7mz9qH_Y6js4kWt6GmPffHuf5PXXuieIhH0O-9FvtDeWLo435qu8nH8YtRb0_vMletbob6O35vs1-fF5-XzzM1l-_rBbz9cxILMeZAU51pW2NGm2rS41kmJDS2AK4kYxsihEg8UIUFTVNUwMBo2TQyELjbbY6cW3QO7WPrtfxoIJ26ncgxI06F6Ea4qkjHEXNrbCy1gwLQoSqBEPGVIn16cTaT01P1pAfo-4uoJcv3m3VJjypWsgKeJEAH86AGH5ONIyqd4OhrtOewjSoNBReSYECkvT9X9JdmKJPrTqqGErJ-DPVRqcCnG9D-tccoWpeClkXaXwyqe7-o0rHUu9M8NS6FL9IYKcEE8MwRGr_1MhAHfdI_bNH-Asav7ow</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2711355120</pqid></control><display><type>article</type><title>Lipid Nanoparticles for mRNA Delivery to Enhance Cancer Immunotherapy</title><source>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</source><source>PubMed Central</source><source>Coronavirus Research Database</source><creator>Wang, Hong-Li ; Wang, Zhi-Gang ; Liu, Shu-Lin</creator><creatorcontrib>Wang, Hong-Li ; Wang, Zhi-Gang ; Liu, Shu-Lin</creatorcontrib><description>Messenger RNA (mRNA) is being developed by researchers as a novel drug for the treatment or prevention of many diseases. However, to enable mRNA to fully exploit its effects in vivo, researchers need to develop safer and more effective mRNA delivery systems that improve mRNA stability and enhance the ability of cells to take up and release mRNA. To date, lipid nanoparticles are promising nanodrug carriers for tumor therapy, which can significantly improve the immunotherapeutic effects of conventional drugs by modulating mRNA delivery, and have attracted widespread interest in the biomedical field. This review focuses on the delivery of mRNA by lipid nanoparticles for cancer treatment. We summarize some common tumor immunotherapy and mRNA delivery strategies, describe the clinical advantages of lipid nanoparticles for mRNA delivery, and provide an outlook on the current challenges and future developments of this technology.</description><identifier>ISSN: 1420-3049</identifier><identifier>EISSN: 1420-3049</identifier><identifier>DOI: 10.3390/molecules27175607</identifier><identifier>PMID: 36080373</identifier><language>eng</language><publisher>Basel: MDPI AG</publisher><subject>Antigens ; Biomedical materials ; Cancer ; Cancer immunotherapy ; Cancer therapies ; Cell growth ; Chemotherapy ; Clinical trials ; Cytokines ; Drug delivery ; Drug therapy ; FDA approval ; Health services ; Human papillomavirus ; Immune system ; Immunotherapy ; Leukemia ; lipid nanoparticles ; Lipids ; Lymphocytes ; Medical research ; Messenger RNA ; mRNA delivery ; mRNA stability ; mRNA vaccines ; Nanoparticles ; Prevention ; Radiation therapy ; Review ; System effectiveness ; Tumor necrosis factor-TNF ; Tumors</subject><ispartof>Molecules (Basel, Switzerland), 2022-08, Vol.27 (17), p.5607</ispartof><rights>COPYRIGHT 2022 MDPI AG</rights><rights>2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2022 by the authors. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c537t-c02e98ad93a3dfa7a3ec1455cd602c51eda7ae03e26468ebbb90e01e0e03c56a3</citedby><cites>FETCH-LOGICAL-c537t-c02e98ad93a3dfa7a3ec1455cd602c51eda7ae03e26468ebbb90e01e0e03c56a3</cites><orcidid>0000-0002-1043-4238</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2711355120/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2711355120?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,38516,43895,44590,53791,53793,74412,75126</link.rule.ids></links><search><creatorcontrib>Wang, Hong-Li</creatorcontrib><creatorcontrib>Wang, Zhi-Gang</creatorcontrib><creatorcontrib>Liu, Shu-Lin</creatorcontrib><title>Lipid Nanoparticles for mRNA Delivery to Enhance Cancer Immunotherapy</title><title>Molecules (Basel, Switzerland)</title><description>Messenger RNA (mRNA) is being developed by researchers as a novel drug for the treatment or prevention of many diseases. However, to enable mRNA to fully exploit its effects in vivo, researchers need to develop safer and more effective mRNA delivery systems that improve mRNA stability and enhance the ability of cells to take up and release mRNA. To date, lipid nanoparticles are promising nanodrug carriers for tumor therapy, which can significantly improve the immunotherapeutic effects of conventional drugs by modulating mRNA delivery, and have attracted widespread interest in the biomedical field. This review focuses on the delivery of mRNA by lipid nanoparticles for cancer treatment. We summarize some common tumor immunotherapy and mRNA delivery strategies, describe the clinical advantages of lipid nanoparticles for mRNA delivery, and provide an outlook on the current challenges and future developments of this technology.</description><subject>Antigens</subject><subject>Biomedical materials</subject><subject>Cancer</subject><subject>Cancer immunotherapy</subject><subject>Cancer therapies</subject><subject>Cell growth</subject><subject>Chemotherapy</subject><subject>Clinical trials</subject><subject>Cytokines</subject><subject>Drug delivery</subject><subject>Drug therapy</subject><subject>FDA approval</subject><subject>Health services</subject><subject>Human papillomavirus</subject><subject>Immune system</subject><subject>Immunotherapy</subject><subject>Leukemia</subject><subject>lipid nanoparticles</subject><subject>Lipids</subject><subject>Lymphocytes</subject><subject>Medical research</subject><subject>Messenger RNA</subject><subject>mRNA delivery</subject><subject>mRNA stability</subject><subject>mRNA vaccines</subject><subject>Nanoparticles</subject><subject>Prevention</subject><subject>Radiation therapy</subject><subject>Review</subject><subject>System effectiveness</subject><subject>Tumor necrosis factor-TNF</subject><subject>Tumors</subject><issn>1420-3049</issn><issn>1420-3049</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>COVID</sourceid><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptklurEzEQxxdRPBf9AL4t-OJLj5NMspcXofRUT6EcQfQ5ZJPZNmU3qdndA_32prbIqUpgMkz-8wtzybJ3DO4Qa_jYh47M1NHAS1bKAsoX2TUTHGYIon75zL_KboZhB8CZYPJ1doUFVIAlXmfLtds7mz9qH_Y6js4kWt6GmPffHuf5PXXuieIhH0O-9FvtDeWLo435qu8nH8YtRb0_vMletbob6O35vs1-fF5-XzzM1l-_rBbz9cxILMeZAU51pW2NGm2rS41kmJDS2AK4kYxsihEg8UIUFTVNUwMBo2TQyELjbbY6cW3QO7WPrtfxoIJ26ncgxI06F6Ea4qkjHEXNrbCy1gwLQoSqBEPGVIn16cTaT01P1pAfo-4uoJcv3m3VJjypWsgKeJEAH86AGH5ONIyqd4OhrtOewjSoNBReSYECkvT9X9JdmKJPrTqqGErJ-DPVRqcCnG9D-tccoWpeClkXaXwyqe7-o0rHUu9M8NS6FL9IYKcEE8MwRGr_1MhAHfdI_bNH-Asav7ow</recordid><startdate>20220831</startdate><enddate>20220831</enddate><creator>Wang, Hong-Li</creator><creator>Wang, Zhi-Gang</creator><creator>Liu, Shu-Lin</creator><general>MDPI AG</general><general>MDPI</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>COVID</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-1043-4238</orcidid></search><sort><creationdate>20220831</creationdate><title>Lipid Nanoparticles for mRNA Delivery to Enhance Cancer Immunotherapy</title><author>Wang, Hong-Li ; Wang, Zhi-Gang ; Liu, Shu-Lin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c537t-c02e98ad93a3dfa7a3ec1455cd602c51eda7ae03e26468ebbb90e01e0e03c56a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Antigens</topic><topic>Biomedical materials</topic><topic>Cancer</topic><topic>Cancer immunotherapy</topic><topic>Cancer therapies</topic><topic>Cell growth</topic><topic>Chemotherapy</topic><topic>Clinical trials</topic><topic>Cytokines</topic><topic>Drug delivery</topic><topic>Drug therapy</topic><topic>FDA approval</topic><topic>Health services</topic><topic>Human papillomavirus</topic><topic>Immune system</topic><topic>Immunotherapy</topic><topic>Leukemia</topic><topic>lipid nanoparticles</topic><topic>Lipids</topic><topic>Lymphocytes</topic><topic>Medical research</topic><topic>Messenger RNA</topic><topic>mRNA delivery</topic><topic>mRNA stability</topic><topic>mRNA vaccines</topic><topic>Nanoparticles</topic><topic>Prevention</topic><topic>Radiation therapy</topic><topic>Review</topic><topic>System effectiveness</topic><topic>Tumor necrosis factor-TNF</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wang, Hong-Li</creatorcontrib><creatorcontrib>Wang, Zhi-Gang</creatorcontrib><creatorcontrib>Liu, Shu-Lin</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Molecules (Basel, Switzerland)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, Hong-Li</au><au>Wang, Zhi-Gang</au><au>Liu, Shu-Lin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Lipid Nanoparticles for mRNA Delivery to Enhance Cancer Immunotherapy</atitle><jtitle>Molecules (Basel, Switzerland)</jtitle><date>2022-08-31</date><risdate>2022</risdate><volume>27</volume><issue>17</issue><spage>5607</spage><pages>5607-</pages><issn>1420-3049</issn><eissn>1420-3049</eissn><abstract>Messenger RNA (mRNA) is being developed by researchers as a novel drug for the treatment or prevention of many diseases. However, to enable mRNA to fully exploit its effects in vivo, researchers need to develop safer and more effective mRNA delivery systems that improve mRNA stability and enhance the ability of cells to take up and release mRNA. To date, lipid nanoparticles are promising nanodrug carriers for tumor therapy, which can significantly improve the immunotherapeutic effects of conventional drugs by modulating mRNA delivery, and have attracted widespread interest in the biomedical field. This review focuses on the delivery of mRNA by lipid nanoparticles for cancer treatment. We summarize some common tumor immunotherapy and mRNA delivery strategies, describe the clinical advantages of lipid nanoparticles for mRNA delivery, and provide an outlook on the current challenges and future developments of this technology.</abstract><cop>Basel</cop><pub>MDPI AG</pub><pmid>36080373</pmid><doi>10.3390/molecules27175607</doi><orcidid>https://orcid.org/0000-0002-1043-4238</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1420-3049
ispartof Molecules (Basel, Switzerland), 2022-08, Vol.27 (17), p.5607
issn 1420-3049
1420-3049
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_be256023492d4d59a136e330870cecc8
source Publicly Available Content Database (Proquest) (PQ_SDU_P3); PubMed Central; Coronavirus Research Database
subjects Antigens
Biomedical materials
Cancer
Cancer immunotherapy
Cancer therapies
Cell growth
Chemotherapy
Clinical trials
Cytokines
Drug delivery
Drug therapy
FDA approval
Health services
Human papillomavirus
Immune system
Immunotherapy
Leukemia
lipid nanoparticles
Lipids
Lymphocytes
Medical research
Messenger RNA
mRNA delivery
mRNA stability
mRNA vaccines
Nanoparticles
Prevention
Radiation therapy
Review
System effectiveness
Tumor necrosis factor-TNF
Tumors
title Lipid Nanoparticles for mRNA Delivery to Enhance Cancer Immunotherapy
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T02%3A37%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Lipid%20Nanoparticles%20for%20mRNA%20Delivery%20to%20Enhance%20Cancer%20Immunotherapy&rft.jtitle=Molecules%20(Basel,%20Switzerland)&rft.au=Wang,%20Hong-Li&rft.date=2022-08-31&rft.volume=27&rft.issue=17&rft.spage=5607&rft.pages=5607-&rft.issn=1420-3049&rft.eissn=1420-3049&rft_id=info:doi/10.3390/molecules27175607&rft_dat=%3Cgale_doaj_%3EA745962145%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c537t-c02e98ad93a3dfa7a3ec1455cd602c51eda7ae03e26468ebbb90e01e0e03c56a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2711355120&rft_id=info:pmid/36080373&rft_galeid=A745962145&rfr_iscdi=true